Nextar Chempharma Solutions Revenue
Pharmaceutical Manufacturing • 
Nes Ziona, Center District, Israel • 21-50 Employees
Nextar Chempharma Solutions revenue & valuation
| Annual revenue | $2,395,540 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $7,700,000 |
| Total funding | No funding |
Key Contacts at Nextar Chempharma Solutions
Daniel Epstein
Director Of Analytical Labs
Madeleine Vaida
Deputy Director Of Analytical Laboratories
Hilla Ben David
Chief Technology Officer
Daniel Epstein
Director Of Analytical Laboratories
Company overview
| Headquarters | Einstein St. 13B, Weizmann Science Park, Ness Ziona, 74140, IL |
| Phone number | +972732244440 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Contract Manufacturing, Formulation Development |
| Founded | 2007 |
| Employees | 21-50 |
| Socials |
Nextar Chempharma Solutions Email Formats
Nextar Chempharma Solutions uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@nextar.co.il), used 38.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@nextar.co.il | 38.9% |
{first initial} | j@nextar.co.il | 22.2% |
{first name} | john@nextar.co.il | 16.7% |
{last name}{first initial} | doej@nextar.co.il | 11.1% |
{first name}.{last name} | john.doe@nextar.co.il | 5.6% |
About Nextar Chempharma Solutions
Nextar Chempharma Solutions Ltd. is an Israeli biotechnology company that develops and manufactures innovative pharmaceuticals and medical devices. The company has helped bring over 180 products to market, both as a contract development and manufacturing organization (CDMO) and for its own portfolio. Nextar has manufacturing capabilities for small-scale sterile and non-sterile products, and its facilities are fully certified and some of the drug products we helped to develop are commercialized globally. Nextar is also developing a proprietary Brain-Transported Liposomes (BTLs) platform, which can deliver generic and innovative drugs across the blood-brain barrier (BBB) into the brain. This platform has the potential to revolutionize the treatment of brain diseases, such as brain cancer and Parkinson's. Nextar's first product based on the BTLs platform is currently in development for the treatment of glioblastoma. In other words, Nextar is a cutting-edge biotechnology company that is developing innovative new treatments for brain diseases. The company's BTLs platform has the potential to revolutionize the way we treat brain-related diseases.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Nextar Chempharma Solutions has 10 employees across 7 departments.
Departments
Number of employees
Funding Data
Nextar Chempharma Solutions has never raised funding before.
Nextar Chempharma Solutions Tech Stack
Discover the technologies and tools that power Nextar Chempharma Solutions's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Issue trackers
Appointment scheduling
PaaS
Blogs
Miscellaneous
Programming languages
Miscellaneous
Security
JavaScript frameworks
Blogs
IaaS
United States
Australia
Belgium
United Kingdom
Frequently asked questions
4.8
40,000 users
